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Volume 58, Number 3 Abstracts 845limb ischemia (Feinglass J et al, Am J Public Health 1999;89:1222-7).
Many amputations fail, and the authors sought to use the American College
of Surgeons (ACS) National Surgical Quality Improvement Program
(NSQIP) database to gather information on predictors and incidence of
early amputation failure. Patients from 2005 to 2010 in the ACS NSQIP
database who underwent isolated lower extremity amputation were included
for analysis. Patients who had a previous operation #30 days, patients
undergoing an open amputation, and patients undergoing another proce-
dure during amputation were excluded from analysis. Predictors of early
amputation failure were determined with multivariate logistic regression
analysis. Early amputation failure was deﬁned as a need for a reoperation
#30 days postoperatively. Data were adjusted for preoperative and intrao-
perative variables. The analysis included 8878 patients who underwent
4258 below-knee amputations (BKA), 3415 above-knee amputations
(AKA), and 1205 transmetatarsal amputations (TMA). The overall rate of
early amputation failure was 12.7%. The rate was 12.6% for BKA, 8.1%
for AKA, and 26.4% for TMA (P < .0001). Preoperative and intraoperative
variables that were independently associated with early amputation failure
included emergency operation, TMA (reference, BKA), sepsis (reference,
no sepsis), septic shock (reference, no sepsis), end-stage renal disease,
systemic inﬂammatory response syndrome (reference, no sepsis), intraoper-
ative surgical trainee participation, body mass index $30 kg/m2, and
continued tobacco use. Characteristics associated with decreased early
amputation failure included age $80 years (reference, <65 years), regional
anesthesia, AKA (reference, BKA), and operative times of 40 to 59 minutes
(reference, <40 minutes), >80 minutes (reference, <40 minutes), and 60
to 79 minutes (reference, <40 minutes).
Comment: These data suggest there are potentially modiﬁable risk
factors for amputation failure. Use of regional rather than general anesthesia
may improve amputation failure rates, spending a bit more time on metic-
ulous surgical technique (ie, a longer operation), and enhanced supervision
of surgical trainees during the performance of the procedure all could
potentially contribute to lower rates of lower extremity amputation failure.
These all seem to be reasonable and relatively easily implemented
suggestions.
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Conclusion: Vorapaxar does not decrease the risk of cardiovascular
death, stroke, or myocardial infarction in patients with peripheral artery
disease (PAD). It does result in reduced limb ischemia and reduced periph-eral revascularization. The beneﬁts on limb vascular events were accompa-
nied by an increased risk of bleeding.
Summary: Vorapaxar is an antagonist of protease-activated receptor-
1, a primary receptor for thrombin on human platelets present on vascular
endothelial and smooth muscle. Patients with PAD are at increased risk of
acute atherothrombotic events complicating atherosclerosis. This includes
myocardial infarction, stroke, and cardiovascular death. Antiplatelet therapy
appears to reduce the risk of cardiovascular events in patients with PAD
(Antithrombotic Trialists’ Collaboration, BMJ 2002;324:71-86). The Pre-
venting Heart Attack and Stroke in Patients with Atherosclerosis
(TRA2P-TIMI 50) trial evaluated the safety and efﬁcacy of vorapaxar
for secondary prevention in patients with established atherosclerosis that
was manifested as prior myocardial infarction, PAD, or ischemic stroke.
Vorapaxar resulted in an overall 13% reduction in major cardiovascular
events (P < .001; Morrow DA et al, Am Heart J 2009;158:335-41.e3).
In this current analysis, investigators focused on the effect of vorapaxar
on peripheral vascular and cardiovascular outcomes in patients qualiﬁed
for TRA2P-TIMI 50 with symptomatic PAD. This was a randomized,
double-blind, placebo-controlled trial of vorapaxar in 26,449 patients
with stable atherosclerotic vascular disease. Patients had PAD as a qualifying
criteria if they had a history of claudication and an ankle-brachial index of
<0.85 or prior revascularization for limb ischemia. There were 3787 such
patients. The primary efﬁcacy end points were cardiovascular death,
myocardial infarction, or stroke, and the principal safety end point was
bleeding. In the PAD cohort, the primary end point did not differ signif-
icantly with vorapaxar (11.3% vs 11.9%; hazard ratio [HR], 0.94; 95%
conﬁdence interval [CI], 0.78-1.14; P ¼ .53). However, rates of hospital-
ization for acute limb ischemia (2.3% vs 3.9%; HR, 0.58; 95% CI, 0.39-
0.86; P ¼ .006) and peripheral artery revascularization (18.4% vs 22.2%;
HR, 0.84; 95% CI, .073-0.97; P ¼ .017) were lower in patients random-
ized to vorapaxar. Bleeding occurred more frequently in patients random-
ized to vorapaxar than to placebo (7.4% vs 4.5%; HR, 1.62; 95% CI, 1.21-
2.18; P ¼ .001).
Comment: Vorapaxar is a novel new antiplatelet agent. It is disap-
pointing the primary efﬁcacy end point of cardiovascular death, myocardial
infarction, or stroke was not achieved in the study. A somewhat surprising
ﬁnding, however, was that the drug signiﬁcantly reduced hospitalization
for acute limb ischemia and peripheral revascularization. This suggests
a potential therapeutic application in patients at high risk for acute limb
ischemic events. Despite the increased risk of bleeding, the drug may have
clinical efﬁcacy in patients at high risk for peripheral vascular events such
as those with previous bypass grafts, angioplasty, or low ankle-brachial
indices. This will need to be studied in a population of patients reﬂective
of these parameters.
